| Ticker | Current Price | % Daily Change | Volume (1,000s) | Average Volumn (1,000s) | Market Cap (Millions) | 1/2/2020 Price | % Change Since Inception 1/2/2020 |
|---|---|---|---|---|---|---|---|
| ABEO | $1.65 | -1.79% | 879 | 1,578 | $165 | $3.21 | -48.6% |
1330 Avenue of the Americas
33rd Floor
New York, NY 10019
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-201 for CLN3 disease. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
